David G McLeod

Summary

Affiliation: Walter Reed Army Medical Center
Country: USA

Publications

  1. ncbi request reprint The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup
    David G McLeod
    Urology Service, Walter Reed Army Medical Center, Washington, D C, USA
    J Urol 176:75-80. 2006
  2. doi request reprint Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues
    David G McLeod
    Center for Prostate Disease Research Urology Service, Uniformed Services University, Walter Reed Army Medical Center, Bethesda, Maryland, USA
    Eur Urol 53:898-9. 2008
  3. ncbi request reprint Hormonal therapy: historical perspective to future directions
    David G McLeod
    Urologic Oncology Clinic, Urology Service, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Urology 61:3-7. 2003
  4. ncbi request reprint Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
    David G McLeod
    Walter Reed Army Medical Center, Washington, DC, USA
    BJU Int 97:247-54. 2006
  5. ncbi request reprint Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer
    Bungo Furusato
    Department of Surgery, United States Military Cancer Institute, Center for Prostate Disease Research, Uniformed Service University of the Health Science, Bethesda, MD, USA
    Mod Pathol 21:67-75. 2008
  6. doi request reprint PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume
    Eric J Whitman
    Urology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Urol 180:1975-8; discussion 1978-9. 2008
  7. ncbi request reprint Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines
    Yongpeng Gu
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Exp Cell Res 312:831-43. 2006
  8. ncbi request reprint Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy
    Inger L Rosner
    Center for Prostate Disease Research, Department of Surgery, and Unites States Military Cancer Institute, Uniformed Services University, Rockville, Maryland 20852, USA
    Urology 70:1225-9. 2007
  9. ncbi request reprint Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells
    Hongzhen Li
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Exp Cell Res 314:92-102. 2008
  10. doi request reprint Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival
    Joseph R Sterbis
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Clin Cancer Res 14:758-63. 2008

Collaborators

Detail Information

Publications72

  1. ncbi request reprint The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup
    David G McLeod
    Urology Service, Walter Reed Army Medical Center, Washington, D C, USA
    J Urol 176:75-80. 2006
    ..We describe the results of North American Trial 23 of the bicalutamide (Casodex) early prostate cancer program in the context of the overall early prostate cancer program findings...
  2. doi request reprint Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues
    David G McLeod
    Center for Prostate Disease Research Urology Service, Uniformed Services University, Walter Reed Army Medical Center, Bethesda, Maryland, USA
    Eur Urol 53:898-9. 2008
  3. ncbi request reprint Hormonal therapy: historical perspective to future directions
    David G McLeod
    Urologic Oncology Clinic, Urology Service, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Urology 61:3-7. 2003
    ..Recent evidence suggests that hormonal therapy may offer a survival benefit when initiated in earlier stages of prostate cancer. Future investigations will be directed to determining the most efficacious regimens...
  4. ncbi request reprint Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
    David G McLeod
    Walter Reed Army Medical Center, Washington, DC, USA
    BJU Int 97:247-54. 2006
    ..To evaluate, in the ongoing Early Prostate Cancer (EPC) trial programme, the efficacy and tolerability of bicalutamide 150 mg once daily in addition to standard care for localized or locally advanced, nonmetastatic prostate cancer...
  5. ncbi request reprint Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer
    Bungo Furusato
    Department of Surgery, United States Military Cancer Institute, Center for Prostate Disease Research, Uniformed Service University of the Health Science, Bethesda, MD, USA
    Mod Pathol 21:67-75. 2008
    ..However, heterogeneity of the TMPRSS2-ERG detection in the context of multiple cancer foci and its frequency in PIN also support the role of other genomic alterations in the origins of prostate cancer...
  6. doi request reprint PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume
    Eric J Whitman
    Urology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Urol 180:1975-8; discussion 1978-9. 2008
    ..Recent studies showed the diagnostic potential of a urine based PCA3 for predicting biopsy outcome. We assessed the relationship between urine PCA3 and pathological features in whole mount radical prostatectomy specimens...
  7. ncbi request reprint Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines
    Yongpeng Gu
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Exp Cell Res 312:831-43. 2006
    ..These novel in vitro models may offer unique models for the study of prostate carcinogenesis and also provide the means for testing both chemopreventive and chemotherapeutic agents...
  8. ncbi request reprint Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy
    Inger L Rosner
    Center for Prostate Disease Research, Department of Surgery, and Unites States Military Cancer Institute, Uniformed Services University, Rockville, Maryland 20852, USA
    Urology 70:1225-9. 2007
    ..Because AR mutations or amplification are rare in early stage CaP, we hypothesized that altered AR expression in prostate tumor cells may provide a prognostic indicator of disease progression...
  9. ncbi request reprint Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells
    Hongzhen Li
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Exp Cell Res 314:92-102. 2008
    ..The results indicate that RC170N/h/clone 7 cells retain the properties of multipotent stem cells and will be useful as a novel cell model for studying the mechanisms of human prostate stem cell differentiation and transformation...
  10. doi request reprint Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival
    Joseph R Sterbis
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Clin Cancer Res 14:758-63. 2008
    ..g., PSA/HK3 mRNA) in CaP tissues will provide in vivo readout of AR dysfunctions. Moreover, quantitative expression features of PSA/HK3 mRNA in prostate tumor cells may serve as a prognostic indicator of disease progression...
  11. ncbi request reprint Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line
    Yongpeng Gu
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Anticancer Res 25:1-8. 2005
    ..NKX 3.1 and epithelial cell specific cytokeratin 8, androgen receptor (AR), prostate stem cell antigen and p16, but not PSA. AR protein was detected by Western blot analysis...
  12. ncbi request reprint Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database
    Judd W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Urol Oncol 21:447-55. 2003
    ..In a broad practice experience represented here, autologous blood donation would appear to be unnecessary for the majority of men and the blood loss advantage traditionally associated with perineal RP is no longer evident...
  13. ncbi request reprint Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens
    Jun Miki
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Cancer Res 67:3153-61. 2007
    ..Expression of CXCR4 was also detected in CD133(+) cancer cells. These novel in vitro models may offer useful tools for the study of the biological features and functional integration of normal and cancer stem cells in prostate...
  14. ncbi request reprint Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era
    Corey A Carter
    Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    J Clin Oncol 21:4001-8. 2003
    ..An analysis of the Department of Defense Center for Prostate Disease Research Database was undertaken to document younger men with low- or intermediate-grade PC who initially chose WW...
  15. ncbi request reprint Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy
    Jason C Massengill
    Department of Surgery, Center for Prostatic Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    J Urol 169:1670-5. 2003
    ..We rigorously tested pretreatment total testosterone levels as a potential staging and prognostic marker in a large cohort of 879 patients with localized cancer treated with radical prostatectomy...
  16. doi request reprint Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer
    Kevin R Rice
    Urology Service, Walter Reed Army Medical Center, Armed Forces Institute of Pathology, Washington, District of Columbia, USA
    Clin Cancer Res 16:1572-6. 2010
    ..This study evaluates the potential of an assay quantitating ERG mRNA in post-digital rectal exam (DRE) urine for improving prostate cancer detection...
  17. ncbi request reprint Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms
    Kevin J Gancarczyk
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urology 61:589-95. 2003
    ..To develop probability nomograms to predict pathologic outcome at the time of radical prostatectomy (RP) on the basis of established prognostic factors and prostate biopsy quantitative histology...
  18. ncbi request reprint Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients
    Matthew T Hueman
    Clinical Breast Care Project, Department of Surgery and Center for Prostate Disease Research, Department of Urology, Walter Reed Army Medical Center, Washington, District of Colombia, USA
    Clin Cancer Res 11:7470-9. 2005
    ..We are conducting a clinical trial of an E75/granulocyte macrophage colony-stimulating factor vaccine to prevent post-prostatectomy prostate-specific antigen (PSA) recurrences in high-risk prostate cancer (HRPC) patients...
  19. doi request reprint Prostate cancer in men less than the age of 50: a comparison of race and outcomes
    Patrick M Parker
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Urology 78:110-5. 2011
    ..We compared clinicopathologic features and survival outcomes for men <50 years of age in relation to other age groups stratified by race to further define CaP in young men...
  20. ncbi request reprint Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients
    Chun Ling Gao
    Center for Prostate Disease Research, Department of Surgery, Uniformed Service University of the Health Science, Bethesda, Maryland 20814 4799, USA
    Clin Cancer Res 9:2545-50. 2003
    ....
  21. ncbi request reprint PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression
    Linda L Xu
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, 1530 East Jefferson Street, Bethesda, MD 20852, USA
    Cancer Res 63:4299-304. 2003
    ..Loss or reduced PMEPA1 expression in CaP further suggests for its role in prostate tumorigenesis...
  22. doi request reprint Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy
    Eric J Whitman
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, District of Columbia, USA
    Cancer Epidemiol Biomarkers Prev 19:1-8. 2010
    ..This study was designed to evaluate associations between 8q24 risk alleles and clinical variables, such as pathologic stage, age at diagnosis, and recurrence, in a case series of African-American men...
  23. doi request reprint Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat
    Kevin R Rice
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, CD 20307, USA
    Urol Oncol 31:755-60. 2013
    ..Prostate cancer (CaP) in the aging male will become an increasingly important and controversial health care issue. We evaluated the outcomes between a variety of treatments for low-risk CaP in patients 70 years of age and older...
  24. ncbi request reprint Lymphovascular invasion in prostate cancer: prognostic significance in patients treated with radiotherapy after radical prostatectomy
    Joseph P Brooks
    Division of Radiation Oncology, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer 106:1521-6. 2006
    ..Although LVI is associated with higher rates of recurrence after RP, its prognostic significance after postprostatectomy radiotherapy (P-XRT) is unclear...
  25. ncbi request reprint Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer
    Michael M Woll
    Divisions of General Surgery and Urology, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Int J Oncol 25:1769-80. 2004
    ..The majority of prostate cancer patients at high risk for recurrence have HER2/neu expressing tumors. Hence, HER2/neu is a viable target for immunotherapeutics such as preventative immunization strategies with HER2/neu peptide vaccines...
  26. ncbi request reprint Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles
    Hongzhen Li
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Int J Oncol 31:537-44. 2007
    ..This model provides an opportunity to study the cellular and molecular alterations that occur in radiation carcinogenesis in human prostate cells...
  27. ncbi request reprint Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors
    Joseph P Brooks
    Section of Radiation Oncology, Department of Urology, Walter Reed Army Medical Center, Washington, D C, USA
    J Urol 174:2204-8, discussion 2208. 2005
    ....
  28. doi request reprint Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors
    Amina Ali
    Urology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Pathol Int 60:667-72. 2010
    ..In the setting of low-volume prostate cancer, CTCs may be associated with the presence of detectable PSA levels. However, the detection of CTCs did not predict PSA failure...
  29. ncbi request reprint Watchful waiting and factors predictive of secondary treatment of localized prostate cancer
    Hongyan Wu
    Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda, MD, USA
    J Urol 171:1111-6. 2004
    ..We defined the demographic, clinical and outcome features of men selecting watchful waiting as an initial treatment strategy, and determined factors predictive of eventual progression to secondary treatment...
  30. ncbi request reprint Emerging role of adjuvant hormonal therapy
    David G McLeod
    Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Urology 60:13-20; discussion 21. 2002
    ..A longer follow-up period will determine whether the reduced risk of progression will translate into cause-specific and overall survival benefit for these patients...
  31. pmc Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men
    James Farrell
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 1530 E Jefferson St, Rockville, MD 20852, USA
    Int J Mol Sci 14:15510-31. 2013
    ..Current and future work will improve the ability to sub-type prostate cancers by molecular alterations and lead to targeted therapy against this common malignancy. ..
  32. ncbi request reprint Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin
    Hongzhen Li
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Int J Oncol 31:601-6. 2007
    ..Our results indicate that the Brazilian propolis extracts show promise as chemotherapeutic agents as well as preventive agents against prostate cancer...
  33. doi request reprint Clinicopathological behavior of single focus prostate adenocarcinoma
    Kevin R Rice
    Urology Service, Walter Reed Army Medical Center, Washington, DC, USA
    J Urol 182:2689-94. 2009
    ..We determined the clinicopathological characteristics and natural history of single focus prostate cancer since this entity seems to be the ideal target for focal therapy...
  34. doi request reprint Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology
    Bungo Furusato
    Center for Prostate Disease Research, Department of Surgery and United States Military Cancer Institute, Uniformed Service University of the Health Science, Bethesda, Maryland, USA
    Urology 75:768-72. 2010
    ..Currently, little is known about the tumor-associated stromal gene expression profile in prostate cancer...
  35. doi request reprint Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes
    Stephen A Brassell
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Urol 185:132-7. 2011
    ..We defined the clinicopathological features and outcomes for men 70 years old or older who were diagnosed with prostate cancer...
  36. ncbi request reprint A novel neoplastic primary tumor-derived human prostate epithelial cell line
    Daejin Ko
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Int J Oncol 22:1311-7. 2003
    ..This is the first documented case of a malignant AR and PSA positive established human prostate cancer cell line from a primary tumor of a prostate cancer patient...
  37. ncbi request reprint Diagnostic potential of serum proteomic patterns in prostate cancer
    Lionel L Banez
    Department of Surgery, Uniformed Armed Services University of the Health Sciences, Bethesda, Maryland, USA
    J Urol 170:442-6. 2003
    ....
  38. ncbi request reprint Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues
    Axel S Merseburger
    Department of Genitourinary Pathology, Armed Forces Institute of Pathology AFIP, Washington, DC 20306 6000, USA
    Oncol Rep 10:223-8. 2003
    ..The TMA technique is probably more informative and reliable in evaluating the prognostic value of homogeneously expressed biomarkers...
  39. ncbi request reprint Colorectal, prostate, and skin cancer screening among Hispanic and White non-Hispanic men, 2000-2005
    Jing Zhou
    US Military Cancer Institute, Washington, District of Columbia, USA
    J Natl Med Assoc 103:343-50. 2011
    ..Screen for Life and some intervention programs included educational materials in Spanish as well as English...
  40. ncbi request reprint Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome
    Gyorgy Petrovics
    Center for Prostate Disease Research CPDR, Department of Surgery and US Military Cancer Institute, Uniformed Services University, Rockville, MD 20852, USA
    Oncogene 24:3847-52. 2005
    ....
  41. ncbi request reprint Perioperative complications of radical retropubic prostatectomy
    Joseph R Sterbis
    Center for Prostate Disease Research CPDR Department of Surgery Uniformed Services University of the Health Sciences Bethesda, MD, USA
    Clin Genitourin Cancer 4:160-6. 2005
    ..The intent of this effort is to review established data regarding the most frequently seen complications and to highlight recent developments regarding the prevention or treatment of such complications...
  42. ncbi request reprint The design and implementation sof a multidisciplinary prostate cancer clinic
    Jane L Hudak
    Center for Prostate Disease Research, Walter Reed Army Medical Center, Washington, DC, USA
    Urol Nurs 27:491-8. 2007
    ..How and why the clinic was designed and implemented, as well as benefits to patients, staff, and research initiatives, are detailed...
  43. ncbi request reprint An assessment of the virtual conversations method for prostate cancer patient education
    WILLIAM G HARLESS
    Interactive Drama Inc, Bethesda, MD, USA
    Urol Nurs 27:499-506. 2007
    ..A voice-activated, interactive, virtual dialogue with a prostate cancer specialist was developed and tested in a clinical setting at the Walter Reed Army Medical Center (WRAMC)...
  44. ncbi request reprint Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer
    Stephen A Brassell
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Curr Opin Urol 15:163-6. 2005
    ..This review highlights developments in prostate cancer imaging that may improve staging and treatment planning for prostate cancer patients...
  45. pmc Sarcoidosis of the prostate
    Bungo Furusato
    Department of Genitourinary Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    J Clin Pathol 60:325-6. 2007
    ..The histological appearance suggested sarcoidosis, which was confirmed by the clinical history. Four years earlier, the patient had been treated for sarcoidosis...
  46. doi request reprint Health-related quality of life for men with prostate cancer--an evaluation of outcomes 12-24 months after treatment
    Stephen A Brassell
    Urology Service, Department of Surgery, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA Center for Prostate Disease Research, Bethesda, MD 20889, USA Electronic address
    Urol Oncol 31:1504-10. 2013
    ..To determine the health-related quality of life (HRQoL) impact of prostate cancer interventions at 2 years post-treatment, and between the 12- and 24-month interval, to better characterize this measure...
  47. ncbi request reprint Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells
    Takehiko Segawa
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Rockville, Maryland, MD 20852, USA
    Oncogene 21:8749-58. 2002
    ..Decreased CaP associated expression of two ER stress responsive genes also suggests that possible abrogation of this pathway in prostate tumorigenesis...
  48. doi request reprint Advances made in the treatment of testicular cancer in the U.S. Military: 1946 to the present
    Dorota J Hawksworth
    Urology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Urol Oncol 27:553-7. 2009
    ..This article reviews historical contributions of the United States Military Medical Departments in the arena of testicular cancer treatment in the post-World War II era...
  49. ncbi request reprint Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients
    Michael M Woll
    Department of General Surgery, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Washington, DC 20307 5001, USA
    J Clin Immunol 24:449-61. 2004
    ..Our findings indicate that the HLA-A2 dimer is a powerful new tool for directly quantifying and monitoring immune responses of antigen-specific T cells in peptide vaccine clinical trials...
  50. ncbi request reprint Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer
    John A Taylor
    Division of Urology, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Urology 60:841-5. 2002
    ..Because criteria for defining the clinical significance of localized prostate cancer has been proposed, the question may be asked whether the increased number of tumors found is clinically significant...
  51. ncbi request reprint Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database
    Judd W Moul
    Urology Service, Dept of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Surgery 132:213-9. 2002
    ....
  52. ncbi request reprint The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL
    Bill P Vanasupa
    Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, Maryland 20852, USA
    Urol Oncol 7:167-72. 2002
    ....
  53. ncbi request reprint Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Resea
    Peter A S Johnstone
    Investigation Department, Naval Medical Center, San Diego, CA 92134, USA
    Int J Radiat Oncol Biol Phys 55:964-9. 2003
    ..The records of the Department of Defense Center for Prostate Disease Research were queried for the biochemical disease-free results of patients after definitive RT and analyzed by age...
  54. ncbi request reprint Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer
    Henry K Tsai
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 107:2597-603. 2006
    ..The authors estimated PCSM after radiation therapy with short-course androgen suppression therapy (RT+AST) or radical prostatectomy (RP) in men with clinically localized, intermediate-risk to high-risk prostate cancer...
  55. ncbi request reprint Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing
    Edmond L Paquette
    Center for Prostate Disease Research, Rockville, Maryland 20852, USA
    Urology 60:756-9. 2002
    ..To determine how the implementation of prostate-specific antigen (PSA) testing has affected disease-specific survival and other characteristics of prostate cancer...
  56. ncbi request reprint Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Researc
    Peter A S Johnstone
    Naval Medical Ctr, San Diego, Calif 92134 1014, USA
    Radiology 225:420-6. 2002
    ..To report on the first collaboration of the Department of Defense Center for Prostate Disease Research concerned with the relationship between African American race and biochemical disease-free outcomes after definitive radiation therapy...
  57. ncbi request reprint Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
    Urology 60:1-6. 2002
  58. ncbi request reprint Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy
    Christopher L Amling
    Department of Urology, Naval Medical Center, 34800 Bob Wilson Drive, San Diego, CA 92134 5000, USA
    J Clin Oncol 22:439-45. 2004
    ....
  59. ncbi request reprint Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure
    Alexandra J Stewart
    Brigham and Women s Hospital, Dana Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 23:6556-60. 2005
    ..2 ng/mL was significantly associated with prostate cancer-specific mortality (PCSM)...
  60. ncbi request reprint Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program
    William A See
    Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    J Urol 168:429-35. 2002
    ..We determine the efficacy and tolerability of bicalutamide as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with clinically localized or locally advanced prostate cancer...
  61. ncbi request reprint Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 109:1290-5. 2007
    ....
  62. ncbi request reprint Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years
    Manfred P Wirth
    Department of Urology, Technical University of Dresden, Dresden, Germany
    J Urol 172:1865-70. 2004
    ..We evaluated the efficacy and tolerability of 150 mg bicalutamide daily given in addition to standard care, in patients with localized or locally advanced prostate cancer...
  63. ncbi request reprint Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
    Judd W Moul
    Department of Surgery, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda 20852, USA
    J Urol 171:1141-7. 2004
    ....
  64. ncbi request reprint Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program
    Peter Iversen
    Department of Urology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark
    Urology 63:928-33. 2004
    ....
  65. ncbi request reprint Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme
    Chris J Tyrrell
    Derriford Hospital, Plymouth, UK
    Radiother Oncol 76:4-10. 2005
    ....
  66. ncbi request reprint The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy
    John A Taylor
    Urology Division, University of Connecticut Health Center, Farmington, CT 06030, USA
    BJU Int 98:540-3. 2006
    ....
  67. ncbi request reprint Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality
    Jason A Efstathiou
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Urology 68:342-7. 2006
    ..A PSA-DT of less than 3 months is a surrogate endpoint for PCSM...
  68. ncbi request reprint Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer
    Rinaa S Punglia
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 110:1973-8. 2007
    ..In this study, the authors evaluated whether PSA velocity was associated with prostate cancer detection and grade at diagnosis after adjusting for established predictors...
  69. doi request reprint Delineation of TMPRSS2-ERG splice variants in prostate cancer
    Ying Hu
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Rockville, Maryland 20852, USA
    Clin Cancer Res 14:4719-25. 2008
    ..However, virtually nothing is known about the nature of full-length transcripts and encoded proteins. This study focuses on qualitative and quantitative features of full-length TMPRSS2-ERG transcripts in prostate cancer...
  70. ncbi request reprint Storm over screening for prostate specific antigen. Give men facts on prostate cancer
    E Darracott Vaughan
    BMJ 324:1392. 2002
  71. ncbi request reprint Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases
    Peter Langenstroer
    Department of Urology, Medical College of Wisconsin, Milwaukee, 53226, USA
    J Urol 171:684-6. 2004
    ..Thus, the present study compares GI effects of flutamide in irradiated and nonirradiated cases...
  72. pmc Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis
    Ai jun Liu
    Department of Pathology, Chinese PLA General Hospital, Beijing 100853, China
    J Zhejiang Univ Sci B 8:853-9. 2007
    ..To investigate molecular alterations associating with prostate carcinoma progression and potentially provide information toward more accurate prognosis/diagnosis...